X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Up 22.6% in January

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 16,610,000 shares, a growth of 22.6% from the January 15th total of 13,550,000 shares. Based on an average daily volume of 5,310,000 shares, the days-to-cover ratio is currently 3.1 days.

Insiders Place Their Bets

In other news, CFO Adam S. Mostafa sold 74,773 shares of X4 Pharmaceuticals stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $33,647.85. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Paula Ragan sold 76,473 shares of X4 Pharmaceuticals stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $34,412.85. Following the sale, the chief executive officer now directly owns 1,087,386 shares in the company, valued at approximately $489,323.70. The trade was a 6.57 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 202,663 shares of company stock valued at $91,198 in the last ninety days. 1.62% of the stock is currently owned by corporate insiders.

Institutional Trading of X4 Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in XFOR. Verition Fund Management LLC acquired a new stake in X4 Pharmaceuticals in the 3rd quarter valued at approximately $30,000. SG Americas Securities LLC acquired a new position in shares of X4 Pharmaceuticals in the third quarter worth $37,000. Atria Wealth Solutions Inc. acquired a new position in shares of X4 Pharmaceuticals in the fourth quarter worth $44,000. Wells Fargo & Company MN grew its stake in shares of X4 Pharmaceuticals by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 78,518 shares of the company’s stock worth $58,000 after acquiring an additional 26,763 shares in the last quarter. Finally, XTX Topco Ltd grew its stake in shares of X4 Pharmaceuticals by 41.7% in the third quarter. XTX Topco Ltd now owns 157,642 shares of the company’s stock worth $106,000 after acquiring an additional 46,397 shares in the last quarter. Institutional investors and hedge funds own 72.03% of the company’s stock.

X4 Pharmaceuticals Stock Up 1.2 %

X4 Pharmaceuticals stock opened at $0.51 on Friday. X4 Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $1.60. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89. The firm has a 50 day moving average price of $0.60 and a 200 day moving average price of $0.59. The company has a market capitalization of $86.72 million, a PE ratio of -5.65 and a beta of 0.12.

Wall Street Analyst Weigh In

Several analysts have recently commented on XFOR shares. Stifel Nicolaus reduced their price target on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $1.50 price target on shares of X4 Pharmaceuticals in a research report on Friday, February 7th.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.